Health News

Salvage therapies may improve survival outcomes of lymphoma patients after allo-HCT

 2 years ago       129 Views

Allogeneic hematopoietic cell transplant (allo-HCT) remains a treatment option for relapsed/refractory (R/R) lymphoma patients who are ineligible for or relapse after autologous HCT.

This study was accepted to be published in Biology of Blood and Marrow Transplantation in January 2018.

The primary endpoint was post-relapse overall survival (PR-OS) with a secondary endpoint to identify risk factors affecting PR-OS.

Targeted therapy interventions included a wide range of treatments including; monoclonal antibodies, antibody drug conjugates, immunomodulators, proteasome inhibitors, histone deacetylase inhibitors and B-cell receptor pathway inhibitors.

Non-targeted therapies included immunosuppression taper alone, cytotoxic chemotherapy and radiation therapy.

The median PR-OS was 47.9 months for HL, 11.3 months for indolent lymphoma and 10.1 months for aggressive non-NHL.

Patients who received targeted therapy had longer PR-OS (38.7 months) compared with patients receiving non-targeted (22.8 months) and no treatment (1.4 months).

The multivariate analysis identified that later relapse after allo-HCT (?130 days) had significantly better PR-OS than early relapse (48.8 vs 6.5 months, P < 0.001).

The main cause of death was documented as disease progression (n = 45).

The authors observed from their study results that the use of salvage therapies could improve survival outcomes in lymphoma patients after allo-HCT and recommend that this patient population are also considered for clinical trials researching targeted therapies.

Author: @DailyCupofYoga


Join the community!

You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.